In the past week, SCPH stock has gone up by 15.00%, with a monthly gain of 6.62% and a quarterly surge of 7.81%. The volatility ratio for the week is 9.69%, and the volatility levels for the last 30 days are 8.34% for scPharmaceuticals Inc The simple moving average for the last 20 days is 3.15% for SCPH stock, with a simple moving average of -4.59% for the last 200 days.
Is It Worth Investing in scPharmaceuticals Inc (NASDAQ: SCPH) Right Now?
Additionally, the 36-month beta value for SCPH is 0.16. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SCPH is 21.82M and currently, short sellers hold a 26.10% ratio of that float. The average trading volume of SCPH on August 12, 2024 was 232.87K shares.
SCPH) stock’s latest price update
The stock of scPharmaceuticals Inc (NASDAQ: SCPH) has increased by 11.55 when compared to last closing price of 4.33. Despite this, the company has experienced a 15.00% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-12 that BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up to 500,000 shares of common stock at a purchase price of $3.999 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrants. The pre-funded warrants have an exercise price of $0.001 per share. All of the shares and the pre-funded warrants are being offered by scPharmaceuticals. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock from the Company at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on August 13, 2024, subject to the satisfaction of customary closing conditions.
Analysts’ Opinion of SCPH
Many brokerage firms have already submitted their reports for SCPH stocks, with Craig Hallum repeating the rating for SCPH by listing it as a “Buy.” The predicted price for SCPH in the upcoming period, according to Craig Hallum is $20 based on the research report published on September 07, 2023 of the previous year 2023.
Cowen, on the other hand, stated in their research note that they expect to see SCPH reach a price target of $25. The rating they have provided for SCPH stocks is “Outperform” according to the report published on December 01st, 2022.
Jefferies gave a rating of “Buy” to SCPH, setting the target price at $14 in the report published on October 21st of the previous year.
SCPH Trading at 10.56% from the 50-Day Moving Average
After a stumble in the market that brought SCPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.51% of loss for the given period.
Volatility was left at 8.34%, however, over the last 30 days, the volatility rate increased by 9.69%, as shares sank -6.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.10% upper at present.
During the last 5 trading sessions, SCPH rose by +5.12%, which changed the moving average for the period of 200-days by -22.00% in comparison to the 20-day moving average, which settled at $4.67. In addition, scPharmaceuticals Inc saw -22.97% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SCPH
Current profitability levels for the company are sitting at:
- -3.39 for the present operating margin
- 0.71 for the gross margin
The net margin for scPharmaceuticals Inc stands at -3.27. The total capital return value is set at -0.9. Equity return is now at value -114.99, with -56.07 for asset returns.
Based on scPharmaceuticals Inc (SCPH), the company’s capital structure generated 0.62 points at debt to capital in total, while cash flow to debt ratio is standing at -1.53. The debt to equity ratio resting at 1.61. The interest coverage ratio of the stock is -14.41.
Currently, EBITDA for the company is -54.77 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 8.65. The receivables turnover for the company is 3.05for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.21.
Conclusion
In conclusion, scPharmaceuticals Inc (SCPH) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
